Launching Multiple Products and Becoming No. 1 in Japan’s Biosimilar Market
First written in FY2020. 8 of 10 entries say "Advanced", first in FY2022-Q2. Latest entry: 2026-09-16.
1 other company's latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「The company is focusing on the psoriasis treatment ustekinumab BS subcutaneous injection 45mg "F," for which sales began in May 2024, and is advancing efforts to expand the biosimilars business by filing applications for marketing approval for 1 new product in September 2024 and 2 in October.」
In connection with the policy of launching multiple products and becoming No. 1 in biosimilars in Japan, it describes concrete progress consisting of the launch of ustekinumab BS and applications for marketing approval for 3 additional products. - FY2024-Q1AdvancedAnnual report
「In addition to the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」 in radiology, we are preparing to begin marketing new products in acute-care medicine: the antineoplastic agent 「レナリドミドカプセル」 for hematology, scheduled for January 2024; the antiarrhythmic agent 「ランジオロール塩酸塩点滴静注用」, scheduled for March 2024; and 「ウステキヌマブBS皮下注」, used to treat plaque psoriasis and psoriatic arthritis when existing treatments are insufficient, scheduled for May 2024.」
In connection with the goal of launching multiple products, it describes the preparatory stage and planned 2024 sales timing for lenalidomide, landiolol hydrochloride and ustekinumab BS. - FY2022AdvancedAnnual report
「In December 2021, the company entered into an asset transfer agreement with 日本製薬株式会社 to assume the marketing authorizations for 4 products: "Foliamin® (injection, tablets and powder 100mg/g)," "Salprep® combination oral solution," "Minclear® oral spray solution 0.8%," and "Osban® disinfectant solution (0.025%, 0.05%, 0.1%, 10% and Osban Rubbing®)," and completed the transfer. Many of these formulations are expected to generate synergies with the future biosimilars business, and the company is working to expand sales as a step toward future biosimilar sales.」
Regarding the transfer of 4 products from 日本製薬株式会社 with a view to future biosimilar sales, it states that the transfer was completed after the agreement was signed. - FY2022-Q2AdvancedAnnual report
「In December 2021, the company entered into an asset transfer agreement with 日本製薬株式会社 to assume the marketing authorizations for 4 products: "Foliamin® (injection, tablets and powder 100mg/g)," "Salprep® combination oral solution," "Minclear® oral spray solution 0.8%," and "Osban® disinfectant solution (0.025%, 0.05%, 0.1%, 10% and Osban Rubbing®)." Many of these formulations are expected to generate synergies with the future biosimilars business, and the company is steadily laying the groundwork for future biosimilar sales.」
It describes the concrete development of the business platform through an asset transfer agreement with 日本製薬株式会社 to assume the marketing authorizations for 4 products, with a view to future biosimilar sales. - FY2021RestatedAnnual report
「The company aims to launch multiple products through collaboration with partners and other initiatives, and to become No. 1 in biosimilars in Japan.」
It continues to pursue the goals of launching multiple products through collaboration with partners and becoming No. 1 in biosimilars in Japan. - FY2020First statedAnnual report
「The company aims to launch multiple products through collaboration with partners and other initiatives, and to become No. 1 in biosimilars in Japan.」
It sets out a new goal of launching multiple biosimilars through collaboration, including its partnership with Alvotech, and becoming No. 1 in Japan.